Loading
Latest filing published 04 Jun 2026 for Oncolytics Biotech Inc., €20k. Read the official filing
No signal scores available.
James Todd Parsons discloses dealings in 2 companies, chiefly DiaMedica Therapeutics Inc. and Oncolytics Biotech Inc. Activity is concentrated on a single trading day, 1 June 2026, with 2 filings.
Not one of the filings records a straightforward purchase or sale on the market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
On 4 June 2026 came the latest disclosure, an option exercise for €20k in Oncolytics Biotech Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations